Significance of Serum Levels of CRP, Lp-PLA2, Leptin and Lipocalin 2 in Patients with Psoriasis

Czech version

Authors: S. Rendárová ¹; K. Ettler ¹; L. Borská ²; J. Krejsek ³; C. Andrýs ³; J. Kremláček ²; V. Řeháček ⁴
Authors‘ workplace: Klinika nemocí kožních a pohlavních, Fakultní nemocnice Hradec Králové, Univerzita Karlova v Praze, Lékařská fakulta v Hradci Králové, přednosta doc. MUDr. Karel Ettler, CSc. ¹; Ústav patologické fyziologie, Univerzita Karlova v Praze, Lékařská fakulta v Hradci Králové, přednosta prof. MUDr. Miroslav Kuba, CSc. ²; Ústav klinické imunologie a alergologie, Fakultní nemocnice Hradec Králové, Univerzita Karlova v Praze, Lékařská fakulta v Hradci Králové, přednosta prof. RNDr. Jan Krejsek, CSc. ³; Transfuzní oddělení Fakultní nemocnice Hradec Králové, primář MUDr. Vít Řeháček ⁴
Published in: Čes-slov Derm, 90, 2015, No. 4, p. 157-163
Category: Pharmacologyand Therapy, Clinical Trials

Overview

Psoriasis is a systemic inflammatory disease. Genetic and environmental factors play a role in its pathogenesis. Recent studies refer to association between psoriasis with metabolic syndrome and cardiovascular disease. In our study we examined changes in serum levels of selected indicators of inflammation such as C-reactive protein (CRP), lipoprotein associated phospholipase A2 (LpPLA2), adiponectin, leptin, lipocalin 2, resistin and retinol binding protein 4 (RBP4). Serum indicators were measured and compared in 32 patients with moderate to severe psoriasis (median PASI 17,1) and in 24 healthy controls (donors of blood). Significantly higher levels of CRP, LpPLA2, lipocalin 2 and leptin were found in patients with psoriasis compared to the control group. Negative correlation were observed between body mass index BMI and adiponectin, positive correlations were found between BMI and leptin and between BMI and lipocalin 2 in patients with psoriasis. Indicators like CRP, LpPLA2, lipocalin 2 and leptin could be used to asses the systemic involvement in psoriasis and to recognition and treatment of psoriatic comorbidities early.

Key words:
psoriasis – comorbidities – C-reactive protein – lipoprotein associated phospholipase A2 – adiponectin – leptin – lipocalin 2 – resistin – retinol binding protein 4

Sources

1. ABDEL HAY, R. M., RASHED, L. A. Association between the leptin gene 2548G/A polymorphism, the plasma leptin and the metabolic syndrome with psoriasis. Exp. Dermatol., 2011, 20, 9, p. 715–719.

2. ABDULLAH, S. M., KHERA, A., LEONARD, D. K. et al. Sex differences in the association between leptin and CRP: results from the Dallas Heart Study. Atherosclerosis, 2007, 195, 2, p. 404–10.

3. ALY, D. G., ABDALLAH, I. Y., HANAFY, N. S. et al. Elevated serum leptin levels in nonobese patients with psoriasis. J. Drugs. Dermatol., 2013, 12, 2, p. 25–29.

4. ATASEVEN, A., KESLI, R., KURTIPEK, G. S. et al. Assessment of Lipocalin 2, Clusterin, Soluble Tumor Necrosis Factor Receptor-1, Interleukin-6, Homocysteine, and Uric Acid Levels in Patients with Psoriasis. Dis. Markers, 2014, p. 7.

5. BARAN, A., FLISIAK, I., JAROSZEWICZ, J. et al. Serum adiponectin and leptin levels in psoriatic patients according to topical treatment. J. Dermatolog. Treat., 2014, p. 1–5.

6. BEYGI, S., LAJEVARDI, V., ABEDINI, R. C-reactive protein in psoriasis: a review of the literature. J. Eur. Acad. Dermatol. Venereol., 2014, 28, 6, p. 700–711.

7. CERMAN, A. A., BOZKURT, S., SAV, A. et al. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br. J. Dermatol., 2008, 159, 4, p. 820–826.

8. COIMBRA, S., OLIVEIRA, H., REIS, F. et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J. Eur. Acad. Dermatol. Venereol., 2010, 24, 7, p. 789–796.

9. ENANY, B., EL ZOHIERY, A. K., ELHILALY, R. et al. Carotid intima-media thickness and serum leptin in psoriasis. Herz, 2012, 37, 5, p. 527–533.

10. FRANEKOVÁ, J., JABOR, A. Fosfolipáza A2 asociovaná s lipoproteiny – nový marker kardiovaskulárního rizika. Postgraduální medicína – PM příloha, 2010, s. 5–16.

11. GERDES, S., OSADTSCHY, S., BUHLES, N. et al. Cardiovascular biomarkers in patients with psoriasis. Exp. Dermatol., 2014, 23, 5, p. 322–325.

12. GERDES, S., OSADTSCHY, S., ROSTAMI-YAZDI, M. et al. Leptin, adiponectin, visfatin and retinol-binding protein-4 – mediators of comorbidities in patients with psoriasis? Exp. Dermatol., 2012, 21, 1, p. 43–47.

13. GULLIVER, W. P. et al. Mortality from psoriasis-related comorbidities in a psoriasis founder population. EADV, 2009, Abstract P1199.

14. HOLZER, M., WOLF, P., INZINGER, M. et al. Anti-psoriatic therapy recovers high-density lipoprotein composition and function. J. Invest. Dermatol., 2014, 34, 3, p. 635–642.

15. CHUNG, H., KWON, H. M., KIM, J. Y. et al. Lipoprotein – associated phospholipase A2 is related to plaque stability and is a potential biomarker for acute coronary syndrome. Yonsei Med. J., 2014, 55, 6, p. 1507–1515.

16. ISHA, JAIN, V. K., LAL, H. C-reactive protein and uric Acid levels in patients with psoriasis. Indian. J. Clin. Biochem., 2011, 26, 3, p. 309–311.

17. JOHNSTON, A., AMADOTTIR, S., GUDJONSSON, J. E. et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br. J. Dermatol., 2008, 159, 2, p. 342–350.

18. KADRY, D., HEGAZY, R. A., RASHED, L. Osteopontin and adiponectin: how far are they related in the complexity of psoriasis? Arch. Dermatol. Res., 2013, 305, 10, p. 939–944.

19. KAMATA, M., TADA, Y., TATSUTA, A. et al. Serum lipocalin-2 levels are increased in patients with psoriasis. Clin. Exp. Dermatol., 2012, 37, 3, p. 296–296.

20. KARADAG, A. S., ERTUGRUL, D. T., KALKAN, G. et al. The effect of acitretin treatment on insulin resistance, retinol-binding protein-4, leptin, and adiponectin in psoriasis vulgaris: a noncontrolled study. Dermatology, 2013, 227, 2, p. 103–108.

21. KHALID, U., HANSEN, P. R., GISLASON, G. H. et al. Psoriasis and new-onset diabetes: a Danish nationwide cohort study. Diabetes Care, 2013, 36, 8, p. 2402–2407.

22. KLEBER, M. E., SIEKMEIER, R., DELGADO, G. et al. C-reactive protein and lipoprotein-associated phospholipase A2 in smokers and nonsmokers of the Ludwigshafen Risk and Cardiovascular Health study. Adv. Exp. Med. Biol., 2015, 832, p. 15–23.

23. KLOK, M. D., JAKOBSDOTTIR, S., DRENT, M. L. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes. Rev., 2007, 8, 1, p. 21–34.

24. LI, R. C., KRISHNAMOORTHY, P., DEROHANNESSIAN, S. et al. Psoriasis is associated with decreased plasma adiponectin levels independently of cardiometabolic risk factors. Clin. Exp. Dermatol., 2014, 39, 1, p. 19–24.

25. LIU, J. T., SONG, E., XU, A. et al. Lipocalin-2 deficiency prevents endothelial dysfunction associated with dietary obesity: role of cytochrome P450 2C inhibition., Br. J. Pharmacol., 2012, 165, 2, p. 520–531.

26. MADANAGOBALANE, S., SANDHYA, V., ANANDAN, S. et al. Circulating adiponectin levels in Indian patients with psoriasis and its relation to metabolic syndrome. Indian. J. Endocrinol. Metab., 2014, 18, 2, p. 191–196.

27. MAEDA, T., TAKEUCHI, K., XIAOLING, P. et al. Lipoprotein-Associated Phospholipase A2 Regulates Macrophage Apoptosis via the Akt and Caspase-7 Pathways. J. Atheroscler. Thromb., 2014, 21, 8, p. 839–853.

28. MARGOLIS, D., BILKER, W., HENNESSY, S. et al. The risk of malignancy associated with psoriasis. Arch. Dermatol., 2001, 137, 6, p. 778–783.

29. NOVOTNY, D., VAVERKOVA, H., KARASEK, D. et al. Adiponektin – parametr s protizánětlivým a protiaterogennim potenciálem. Klin. Biochem. Metab., 2008, 16, 37, s. 171–177.

30. OH, Y. J., LIM, H. K., CHOI, J. H. et al. Serum leptin and adiponectin levels in Korean patients with psoriasis. J. Korean. Med. Sci., 2014, 29, 5, p. 729–734.

31. ROMANI, J., CAIXAS, A., CEPERUELO-MALLAFRE, V. et al. Circulating levels of lipocalin-2 and retinol-binding protein-4 are increased in psoriatic patients and correlated with baseline PASI. Arch. Dermatol. Res., 2013, 305, 2, p. 105–112.

32. SEN, B. B., RIFALIOGLU, E. N., EKIZ, O. et al. Are plasma resistin and omentin levels different in patients with psoriasis with or without atherosclerosis? Arch. Dermatol. Res., 2013, 305, 5, p. 457–458.

33. SCHMITT, J., GOTTFRIED, W. The Psoriasis Area and Severity Index Is the Adequate Criterion to Define Severity in Chronic Plaque-Type Psoriasis. Dermatology, 2005, 210, p. 194–199.

34. SIEGEL, D., DEVARAJ, S., MITRA, A. et al. Inflammation, atherosclerosis, and psoriasis. Clin. Rev. Allergy Immunol., 2013, 44, 2, p. 194–204.

35. TAKAHASHI, H., TSUJI, H., HONMA, M. et al. Increased plasma resistin and decreased omentin levels in Japanese patients with psoriasis. Arch. Dermatol. Res., 2013, 305, 2, p. 113–116.

36. WAN, J., WANG, S., HAYNES, K. et al. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. BMJ. 2013, 347.

37. XU, T., ZHANG, Y. H. Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies. Br. J. Dermatol., 2012, 167, 6, p. 1345–1350.

38. ZHU, K. J., ZHANG, C., LI, M. et al. Leptin levels in patients with psoriasis: a meta-analysis. Clin. Exp. Dermatol., 2013, 38, 5, p. 478–483.

Labels

Dermatology & STDs Paediatric dermatology & STDs Clinical microbiology Paediatrics General practitioner for children and adolescents General practitioner for adults

Autoinflammatory Syndromes with Skin Manifestations

Coincidence of Five Primary Melanomas in One Patient

Article was published in

Czech-Slovak Dermatology

2015 Issue 4